SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 56.98+1.1%Nov 5 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: JOEBT1 who wrote (1147)5/30/2000 10:50:00 PM
From: Miljenko Zuanic  Read Replies (1) of 52153
 
JOEBT1,

I never done in-dept analysis of IMGN, so may be of little help.

IMGN cough my ayes with IND (SKB) and recent deal with DNA (herceptin). However, I am bit skeptical about *tumor activated* pro-drug technology. I agree that bounding toxic agent with selective and specific mAb will increase drug efficiency (increased therapeutic index), but will not claim that this combination isn't toxic (systemic therapy).

Anyway, it will be interesting to follow SKB PI trial and what type of results they will report.

Regards,

Miljenko
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News